Viral Vector Process Development and Manufacturing Summit on February 19-21, 2025 in Boston, United States

The 3rd Viral Vector Process Development and Manufacturing Summit

Enhancing Scale-Up, Increasing Quality, and Reducing Costs for AVs, LVVs, AAVs and More

The 3rd Viral Vector Process Development and Manufacturing Summit returns to Boston, uniting industry leaders from the likes of Sanofi, Kite, Ultragenyx, Sangamo, UCB, and more to focus on advancing the production of viral vectors for cell and gene therapeutics.

2024 has been pivotal for viral vector manufacturing, with more gene therapies in market and regulatory frameworks evolving to support scalable production. With 800+ gene therapy candidates in clinical trials, the focus is on optimizing processes to reduce costs and improve consistency.

Don't miss the only summit dedicated to viral vector process development and manufacturing, featuring talks, panels, roundtables, and 2 interactive workshops. Gain valuable insights into the regulatory landscape and data-driven presentations across upstream and downstream process development on key topics such as:

- Elevating Yield, Titer, and Potency

- Improving Capsid Ratios

- Advancing Purification Techniques

- Enhancing Scale-Up

- Seamless Tech Transfer

- Enhancing Vector Optimization

… and more!

URLs:

Tickets: https://go.evvnt.com/2741205-2?pid=10008

Brochure: https://go.evvnt.com/2741205-3?pid=10008

Time: 9:00 AM - 5:00 PM

Prices:

Full Conference Access - Drug Developer: USD 4197.00,

Conference + 1 Workshop - Drug Developer: USD 3598.00,

Conference Only - Drug Developer: USD 2999.00,

Full Conference Access - Academics and Research Institute: USD 3597.00,

Conference + 1 Workshop - Academic and Research Institute: USD 3098.00,

Conference Only - Academic and Research Institute: USD 2599.00,

Full Conference Access - Service Provider: USD 5097.00,

Conference + 1 Workshop - Service Provider: USD 4398.00,

Conference Only - Service Provider: USD 3699.00

Speakers: Andrew Steinsapir, Acting Chief Technology Officer, Apertura Gene Therapy, April Sena, Vice President, Technical Operations, Life Edit Therapeutics, Ashutosh Gupta, Director - Drug Substance Process Development and Manufacturing, Kiniksa Pharmaceuticals, Ishtiaq Khaliq, Gene Therapy and Molecular Biology Sciences Lead, UCB S.A., Jingying Xu, Director - Regulatory Affairs Chemistry Manufacturing and Controls, Kite, a Gilead Company, Jorge Santiago-Ortiz, Senior Director - Chemistry, Manufacturing, and Controls, Apertura Gene Therapy, Kathy Nguyen, Engineer IV, Takeda Pharmaceutical Co. Ltd, Kok Seong Lim, Analytical Sciences and Quality Control Expert, Independent Expert, Matthew Weaver, Senior Director - Chemistry, Manufacturing and Control Developability, Spirovant Sciences, Michael Datillo, Senior Investigator, Lentiviral Vector Manufacturing Excellence, Johnson and Johnson Services, Inc, Michael DiBiasio-White, Senior Scientist, Ring Therapeutics, Rekha Iyengar, Senior Scientist Upstream Vector Development, Stanford University, Tony Chikere, Director, Vector Process Development, Sangamo Therapeutics, Valerie Ng, Associate Director - Regulatory Affairs, Chemistry, Manufacturing and Controls, Kite, a Gilead Company, Ying Cai, Executive Director - Manufacturing Sciences and Technology, Ultragenyx Pharmaceutical Inc, Yuanli Song, Associate Director, Sanofi